StayWell to Exhibit Krames Clinical Solutions at 2017 International MUSE Conference

Brian Botos News Releases, StayWell News

News release

StayWell to Exhibit Krames Clinical Solutions at 2017 International MUSE Conference

Visit booth 934 to see how latest evidence-based and standards-of-care clinical content can improve patient outcomes

Yardley, PA (May 30, 2017)StayWell, a leading heath solutions provider, announced today it will showcase its Krames clinical patient education solutions during the 2017 International Medical Users Software Exchange (MUSE), May 30-June 2 in Dallas, TX.

Clinicians attending the show can visit booth 934 to learn how Krames Patient Education solutions from StayWell integrate with the MEDITECH electronic health record (EHR) to improve workflow and increase patient education. Krames’ long history of superior patient education is complemented by digital, interactive, and video solutions that integrate easily through the MEDITECH patient discharge instruction (PDI) process.

Krames Patient Education solutions enable clinicians to improve outcomes and patient satisfaction by delivering customized content that meets the needs of individual patients, while supporting the business and marketing needs of their hospital or health system.

“Our patient education solutions improve health literacy and support behavior change, which can also improve patient satisfaction and clinical workflows,” said JoAnna Brogdon, Vice President, Strategic Partnerships, StayWell. “By integrating patient instructions and information into the MEDITECH EHR, we help clinicians meet meaningful use requirements and support their efforts to increase patient satisfaction with customizable content.”

StayWell offers a comprehensive suite of patient education and engagement solutions such as Krames On-Demand®, which gives providers one-click access to:

  • 4,000+ patient education HealthSheets™ on diseases, conditions, procedures, and wellness topics
  • 1,100 emergency room discharge and urgent care instructions
  • 2,900+ drug information sheets
  • 370+ lab tests
  • 190+ patient education videos in both English and Spanish
  • 425+ patient experience videos in English
  • 71 image-only documents

Krames content covers dozens of medical specialty areas and is accessible from the MEDITECH EHR through the Health Level Seven® (HL7) Infobutton and the Krames On-Demand application, which provides access to the StayWell video library and materials in as many as 15 languages.

The 2017 MUSE conference, presented by International Medical Users Software Exchange, gives MEDITECH users an opportunity to discover best practices in patient engagement and education through networking with fellow attendees and exhibitors. Visit Krames Patient Education at booth 934 or online at staywell.com to learn more.

 

###

About StayWell

StayWell is a health solutions company that uses the science of behavior change to help people live happier, healthier lives. StayWell brings decades of experience working across the health care industry to design solutions for improving individual and organizational health outcomes, managing the health of targeted populations, and creating brand engagement for employers and health care organizations. StayWell programs have received numerous top industry honors, including the C. Everett Koop National Health Award and the Web Health Award for health engagement programs. StayWell also has received URAC and NCQA accreditation for several of its programs. StayWell is majority-owned by Healthcare Services & Solutions, LLC, a wholly owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (“Merck”). The company is headquartered in Yardley, PA, and also has a major location in St. Paul, MN. To learn more, visit http://www.staywell.com.

 

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of The StayWell Company, a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

 

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

 

 

Media contact / Barbara Tabor, APR / 651-230-9192 / barbara@taborPR.com